Jeronselvain Delivers Lecture at 'Korean Association of Clinical Aesthetic Surgery'... Unveils PDRN-Based Regenerative Solutions

Jeronselvain, a company specializing in the production of prescription pharmaceuticals, announced on March 3 that it participated as a speaker at the 'Spring Conference of the Korean Association of Clinical Aesthetic Surgery (KACS)', held at COEX in Seoul, delivering a lecture on the topic of 'The Truth About PDRN and Regenerative Therapy'.

At the 'Spring Conference of the Korean Association of Clinical Aesthetic Surgery', Jeronselvain introduced regenerative medicine-based skin rejuvenation strategies and the latest clinical trends, focusing on its core product, 'Selvain Injection'.

This conference provided a platform for sharing the latest technologies and clinical cases in the fields of dermatology, obesity, and plastic surgery, and was attended by more than 1,500 domestic medical professionals and industry representatives.

In his lecture, Deokgyu Kim, CEO of Jeronselvain, presented skin improvement strategies using regenerative medicine-based materials, as well as the technological features of 'Selvain Injection', clinical application cases, and the potential for market expansion.

He particularly emphasized the role of bio-based solutions and differentiated approaches in the fields of skin regeneration and aesthetics.

Jeronselvain is strengthening its product competitiveness in the medical and cosmetic dermatology markets based on regenerative medicine technology, and is pursuing strategies to expand into domestic and international markets centered around 'Selvain Injection'.

Deokgyu Kim, CEO of Jeronselvain, stated, "'Selvain Injection' is a solution that can present a new treatment paradigm in the field of aesthetic medicine through a regenerative medicine-based approach," and added, "Through this lecture, we aim to raise awareness among medical professionals and strengthen brand trust based on scientific evidence."

He further remarked, "As regenerative medicine technology is rapidly being applied in the cosmetic dermatology market, the clinical applications of 'Selvain Injection' are also expected to expand continuously. We anticipate that this will serve as an opportunity to share clinical experiences and the latest trends, and to strengthen collaboration with medical professionals."

This content was produced with the assistance of AI translation services.